NEWS

PRESS RELEASE

Vesalio appoints VP of U.S. Sales and announces recent publication on Ne...

Nashville, Tennessee - (NOV 29, 2022) – VESALIO is pleased to welcome Bob Bushok as Vice President of U.S. Sales overseeing commercial strategy and execution for the NeVa VSTM vasospasm launch and the expected 2023 introduction of NeVa™ thrombectomy platform into the U.S. market. Bob will be responsible for building the U.S. sales team and will play a pivotal role in continuing to grow the company through strategic initiatives.

PRESS RELEASE

Vesalio announces EU MDR Certification

Nashville, Tennessee - (OCT 13, 2022) – VESALIO announces the EU MDR certification of its product lines significantly ahead of the May 2023 deadline. This important milestone marks the third in a series of recent regulatory achievements along with the CE marking of NeVa NET™, VESALIO’s new, flagship neuro-thrombectomy device containing a unique integrated distal filter technology and the FDA HDE approval of NeVa VS™, indicated for the adjunctive treatment of aSAH-induced cerebral vasospasm. NeVa VS is the first medical device approved in the U.S. for this indication.

PRESS RELEASE

Vesalio announces FDA Approval of the NeVa VS™ to treat cerebral vasospa...

Nashville, Tennessee - (Sept 15, 2022) – Vesalio announces FDA HDE approval for commercialization of NeVa VS, indicated for the adjunct treatment of symptomatic cerebral vasospasm (CV) following aneurysmal subarachnoid hemorrhage (aSAH), the major cause of death and disability in this patient population.  This is the first intracranial technology approved for this indication in the U.S.

PRESS RELEASE

Wallaby / phenox announces global launch of the pEGASUS HPC Stent System...

Nice, France (September 7, 2022). Wallaby / phenox has announced the successful global launch of their novel pEGASUS HPC stent at the ESMINT 2022 congress in Nice, France. The introduction of the pEGASUS stent enables more patients to benefit from the HPC surface modification in stent-assisted coiling treatments as well as intracranial atherosclerotic diseases (ICAD) and dissections. The application of the surface modification to the stent results in enhanced safety by significantly reducing thrombogenic complications. 

PRESS RELEASE

Vesalio announces CE Approval for new NeVa NET™, the first integrated cl...

Nashville, Tennessee - (September 1, 2022) – In further expansion of their high-performance thrombectomy portfolio, Vesalio announced CE approval for commercialization of the new NeVa NET, the first and only thrombectomy device with an integrated clot micro-filtration technology. This one-of-a-kind stent retriever combines the company’s proprietary Drop Zone technology, proven to work on all clot types, with a finely braided micro-filter net element integrated into the closed distal tip of the device.

PRESS RELEASE

Vesalio announces oversubscribed class A financing

Nashville, TN – (May 18, 2022) – Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round. Solas BioVentures led the investment with participation by new and existing investors, including the recent addition of Orlando Health Ventures.

PRESS RELEASE

Vesalio Announces the Completion of Enrollment in Its FDA IDE Clinical S...

Nashville, TN May 11, 2022 --(  PR.com  )-- Vesalio is excited to announce the completion of patient enrollment for the CLEAR(1) FDA IDE study utilizing the NeVa™ thrombectomy platform. This is an important milestone for Vesalio to complete for entering the U.S. neurovascular market to treat patients suffering from acute ischemic stroke (AIS).

PRESS RELEASE

MicroVention Announces First Patient Enrolled in the STRAIT Study with t...

Aliso Viejo, CA – April 20, 2022 – MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the successful completion of its first enrollment in a multi-center, prospective EU observational study called STRAIT, to evaluate the Safety and Performance of the BOBBY Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke.

PRESS RELEASE

Vesalio Announces Earl Slee as New Board Observer and Senior Advisor to...

Nashville, TN (February 3, 2022) – Vesalio is pleased to announce the addition of Earl Slee as a board observer and senior advisor to the company, effective immediately.

PRESS RELEASE

Vesalio Announces Appointment of Mike Kujak as its New Independent Board...

Nashville, TN, January 19, 2022 – Vesalio is pleased to announce the appointment of Mike Kujak as chairman of its Board of Directors. In this role, Mike will bring expert knowledge and know-how from his years of leadership in the medical device start-up space.